Your English writing platform
Discover LudwigSuggestions(4)
Exact(1)
Dendritic cell based immunotherapy has been used extensively to counteract the GBM immune-evasion characteristics.
Similar(59)
Based on these observations, the major focus of cancer-specific DC-based immunotherapy has been shifting toward the improvement of overall survival and QOL including performance status.
DC-based immunotherapy has been successfully used for treating many aggressive cancers [4 6].
Therefore, DC-based immunotherapy has been one of the hotspots in cancer immunotherapy in recent years.
Peptide-based immunotherapy has been proposed as one of new strategies for reduction of allergic adverse reactions.
The clinical investigation of CAR-modified NK cell-based immunotherapy has been intensively conducted for several types of cancer (Rezvani and Rouce, 2015).
T-cell-based immunotherapy has been proposed as a novel therapeutic approach to improve the clinical outcome for HNSCC.
In this review, we discuss how pDCs could be exploited in the fight against cancer by analyzing their capacity to capture, process and (cross-) present antigen.> -wrap-foot> activationivation, pDC-derived type I IFNs and mDC-derived IL-12 are involved in the differentiation of Th1 cells Most DC-based immunotherapy has been performed with monocyte-derived DCs that were generated ex vivo [ 11– 13].
Recently, T-cell based immunotherapy has gained some clinical success in prostate cancer and validated the potential of anti-cancer vaccination which was often demonstrated preclinically [ 7].
Based on an overall assessment of this information, a 30-minute waiting period for all patients receiving allergen immunotherapy has been suggested.
Cancer immunotherapy has been a hot startup investment space for a number of years now.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com